Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Tue Mar 31, 7:12AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRK), OmniAb (OABI) and Boston Scientific (BSX) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Merck & Company (MRK)

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company, with a price target of $135.00. The company’s shares closed last Friday at $119.63.

According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 8.3% and a 52.2% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Terns Pharmaceuticals. ;'>

Currently, the analyst consensus on Merck & Company is a Moderate Buy with an average price target of $131.36, which is a 10.1% upside from current levels. In a report issued on March 19, Scotiabank also maintained a Buy rating on the stock with a $136.00 price target.

See the top stocks recommended by analysts >>

OmniAb (OABI)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on OmniAb today. The company’s shares closed last Friday at $1.51.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 15.1% and a 51.9% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Protagonist Therapeutics, and Madrigal Pharmaceuticals. ;'>

OmniAb has an analyst consensus of Strong Buy, with a price target consensus of $7.67.

Boston Scientific (BSX)

In a report released today, Vijay Kumar from Evercore ISI maintained a Buy rating on Boston Scientific, with a price target of $96.00. The company’s shares closed last Friday at $69.17, close to its 52-week low of $66.80.

According to TipRanks.com, Kumar is a 2-star analyst with an average return of 0.0% and a 44.2% success rate. Kumar covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, West Pharmaceutical Services, and Bausch + Lomb Corporation. ;'>

Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $105.14, implying a 50.1% upside from current levels. In a report issued on March 18, Truist Financial also maintained a Buy rating on the stock.

Read More on MRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).